Table 5. Best responses to combined bortezomib/hydroxychloroquine, by prior response to bortezomib, including all subjects evaluable for response.

	VGPR	PR	MR	SD	PD		≥ PR	≥ MR
Bortezomib naïve	3			4	1		38%	38%
Bortezomib responsive			1	2	1		0	25%
Bortezomib refractory			2	4	4		0	20%

PD, progressive disease; VGPR, very good partial response; PR, partial response; MR, minor response; SD, stable disease